[{"id":"ef3ee7ea-e266-49a7-bd2d-0c9eccee4dcb","acronym":"EvoPAR-PR02","url":"https://clinicaltrials.gov/study/NCT06952803","created_at":"2025-06-07T14:51:41.431Z","updated_at":"2025-06-07T14:51:41.431Z","phase":"Phase 3","brief_title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","source_id_and_acronym":"NCT06952803 - EvoPAR-PR02","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • saruparib (AZD5305)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 05/30/2025","start_date":" 05/30/2025","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 04/30/2036","study_completion_date":" 04/30/2036","last_update_posted":"2025-05-30"},{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"a7bc76a3-7767-4569-b28f-313c198056ba","acronym":"MAGNITUDE","url":"https://clinicaltrials.gov/study/NCT03748641","created_at":"2021-01-18T18:22:54.153Z","updated_at":"2025-02-25T13:52:43.687Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03748641 - MAGNITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 765","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2025-02-20"},{"id":"74783677-e3f5-4018-b600-ee9dd649695b","acronym":"ST101-101","url":"https://clinicaltrials.gov/study/NCT04478279","created_at":"2021-01-18T21:30:28.794Z","updated_at":"2025-02-25T14:07:48.179Z","phase":"Phase 1/2","brief_title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04478279 - ST101-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" HR positive • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"b328f4e5-105e-4a5c-a45f-4777aede9baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457257","created_at":"2022-07-13T11:56:53.469Z","updated_at":"2025-02-25T16:17:55.903Z","phase":"Phase 4","brief_title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","source_id_and_acronym":"NCT05457257","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"021a5f18-f5e7-498d-a188-e4903f2c76f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588609","created_at":"2022-10-20T14:11:50.019Z","updated_at":"2025-02-25T16:54:29.545Z","phase":"Phase 2","brief_title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","source_id_and_acronym":"NCT05588609","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-04"},{"id":"58481425-6a53-4802-b306-7ed470c87380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221542","created_at":"2021-01-18T20:32:52.184Z","updated_at":"2025-02-25T16:52:48.663Z","phase":"Phase 1","brief_title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04221542","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 08/17/2028","study_completion_date":" 08/17/2028","last_update_posted":"2025-02-04"},{"id":"da831d56-b69a-4333-9086-5a3e811681fc","acronym":"AMPLITUDE","url":"https://clinicaltrials.gov/study/NCT04497844","created_at":"2021-01-18T21:32:59.167Z","updated_at":"2025-02-25T17:00:35.684Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","source_id_and_acronym":"NCT04497844 - AMPLITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 696","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 01/07/2025","primary_completion_date":" 01/07/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-03"},{"id":"e9087e98-84d9-4794-8123-a03a7c489eac","acronym":"CHAARTED2","url":"https://clinicaltrials.gov/study/NCT03419234","created_at":"2025-02-25T17:35:55.932Z","updated_at":"2025-02-25T17:35:55.932Z","phase":"Phase 2","brief_title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","source_id_and_acronym":"NCT03419234 - CHAARTED2","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 04/26/2018","start_date":" 04/26/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-29"},{"id":"171e76bb-7521-479f-b3fa-159564cab21b","acronym":"PROpelSub","url":"https://clinicaltrials.gov/study/NCT05171816","created_at":"2021-12-29T14:53:52.881Z","updated_at":"2025-02-25T16:17:05.784Z","phase":"Phase 3","brief_title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","source_id_and_acronym":"NCT05171816 - PROpelSub","lead_sponsor":"AstraZeneca","biomarkers":" HRD","pipe":" | ","alterations":" BRCA1 mutation","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • abiraterone acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 06/24/2021","start_date":" 06/24/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 04/28/2026","study_completion_date":" 04/28/2026","last_update_posted":"2025-01-03"},{"id":"24120569-a11a-43a3-9af9-fba2afe807bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01650194","created_at":"2025-02-26T07:28:26.006Z","updated_at":"2025-02-26T07:28:26.006Z","phase":"Phase 2","brief_title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","source_id_and_acronym":"NCT01650194","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 07/09/2012","start_date":" 07/09/2012","primary_txt":" Primary completion: 01/04/2018","primary_completion_date":" 01/04/2018","study_txt":" Completion: 01/04/2018","study_completion_date":" 01/04/2018","last_update_posted":"2024-12-10"},{"id":"4f93e955-11c6-47ce-a489-6d1e7a1b3636","acronym":"PROPEL","url":"https://clinicaltrials.gov/study/NCT03732820","created_at":"2021-01-18T18:17:30.180Z","updated_at":"2025-02-25T16:08:35.182Z","phase":"Phase 3","brief_title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT03732820 - PROPEL","lead_sponsor":"AstraZeneca","biomarkers":" HRD","pipe":" | ","alterations":" BRCA1 mutation","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • abiraterone acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 07/30/2021","primary_completion_date":" 07/30/2021","study_txt":" Completion: 11/04/2024","study_completion_date":" 11/04/2024","last_update_posted":"2024-10-08"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"3d98dd1f-987f-4c68-94e3-38adc1f3cdfa","acronym":"BAT-RAD","url":"https://clinicaltrials.gov/study/NCT04704505","created_at":"2021-01-19T20:51:15.415Z","updated_at":"2025-02-25T17:24:58.474Z","phase":"Phase 2","brief_title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04704505 - BAT-RAD","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-18"},{"id":"34637cf2-d41a-41b6-a1f9-4f46ac1afd16","acronym":"","url":"https://clinicaltrials.gov/study/NCT03436654","created_at":"2021-01-19T15:34:33.162Z","updated_at":"2024-07-02T16:34:27.070Z","phase":"Phase 2","brief_title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","source_id_and_acronym":"NCT03436654","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 02/14/2025","primary_completion_date":" 02/14/2025","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2024-06-11"},{"id":"64151ea0-5e4f-4551-a71f-36af8cc5de9e","acronym":"IPATential150","url":"https://clinicaltrials.gov/study/NCT03072238","created_at":"2021-01-17T17:45:45.867Z","updated_at":"2024-07-02T16:34:37.052Z","phase":"Phase 3","brief_title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03072238 - IPATential150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • ipatasertib (RG7440) • prednisone • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 1101","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/16/2020","primary_completion_date":" 03/16/2020","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2024-06-07"},{"id":"0ed5b400-4576-472b-ab4d-5b13bfb5010f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03860987","created_at":"2021-01-18T19:02:51.031Z","updated_at":"2024-07-02T16:34:37.919Z","phase":"Phase 2","brief_title":"Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer","source_id_and_acronym":"NCT03860987","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-05"},{"id":"1315f5e9-3b04-4aab-a843-bdf4b3d84f6e","acronym":"SNARE","url":"https://clinicaltrials.gov/study/NCT05593497","created_at":"2022-10-25T13:56:29.819Z","updated_at":"2024-07-02T16:34:59.265Z","phase":"Phase 2","brief_title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","source_id_and_acronym":"NCT05593497 - SNARE","lead_sponsor":"VA Office of Research and Development","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Truqap (capivasertib) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-06-04"},{"id":"d5547275-acd2-4edc-8fac-11affa680d28","acronym":"CELLO-1","url":"https://clinicaltrials.gov/study/NCT04179864","created_at":"2021-01-18T20:22:59.772Z","updated_at":"2024-07-02T16:34:59.510Z","phase":"Phase 1/2","brief_title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","source_id_and_acronym":"NCT04179864 - CELLO-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":"","alterations":" ","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-06-03"},{"id":"40f5121b-bb06-4c08-8167-45765aada070","acronym":"KCP-8602-801","url":"https://clinicaltrials.gov/study/NCT02649790","created_at":"2021-01-17T17:34:58.356Z","updated_at":"2024-07-02T16:35:00.978Z","phase":"Phase 1/2","brief_title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","source_id_and_acronym":"NCT02649790 - KCP-8602-801","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • dexamethasone • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 277","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-24"},{"id":"e7e67f7b-9177-413b-a9cc-3fc2a278fefe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577833","created_at":"2021-01-18T21:51:05.666Z","updated_at":"2024-07-02T16:35:01.336Z","phase":"Phase 1","brief_title":"A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","source_id_and_acronym":"NCT04577833","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 11/13/2020","start_date":" 11/13/2020","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 12/05/2025","study_completion_date":" 12/05/2025","last_update_posted":"2024-05-23"},{"id":"d79bfdb8-ad5a-46da-91a6-a2f9ca67b203","acronym":"DynaMO","url":"https://clinicaltrials.gov/study/NCT02703623","created_at":"2021-01-18T13:12:02.865Z","updated_at":"2024-07-02T16:35:03.313Z","phase":"Phase 2","brief_title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02703623 - DynaMO","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 05/18/2016","start_date":" 05/18/2016","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-16"},{"id":"f180fa4a-86d7-4c90-bf6f-101d2893b440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05689021","created_at":"2023-01-18T14:59:57.536Z","updated_at":"2024-07-02T16:35:04.068Z","phase":"Phase 2","brief_title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","source_id_and_acronym":"NCT05689021","lead_sponsor":"Mayo Clinic","biomarkers":" SPOP","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-13"},{"id":"d69f4d60-888a-44f8-a2da-88505cf7f180","acronym":"CAPItello-281","url":"https://clinicaltrials.gov/study/NCT04493853","created_at":"2021-01-18T21:35:12.569Z","updated_at":"2024-07-02T16:35:07.673Z","phase":"Phase 3","brief_title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","source_id_and_acronym":"NCT04493853 - CAPItello-281","lead_sponsor":"AstraZeneca","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1012","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 10/04/2024","primary_completion_date":" 10/04/2024","study_txt":" Completion: 03/26/2027","study_completion_date":" 03/26/2027","last_update_posted":"2024-04-25"}]